Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Tuesday

Artiva Biotherapeutics (NASDAQ:ARTV) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

Artiva Biotherapeutics Trading Up 5.1 %

ARTV opened at $5.36 on Monday. The firm has a 50-day moving average price of $6.06 and a 200-day moving average price of $9.88. Artiva Biotherapeutics has a twelve month low of $3.37 and a twelve month high of $17.31.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ARTV. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright started coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $21.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.